| Neoadjuvant treatment for triple negative breast cancer: recent progresses and challenges JS Lee, SE Yost, Y Yuan Cancers 12 (6), 1404, 2020 | 128 | 2020 |
| Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer JS Lee, ME Melisko, MJM Magbanua, AT Kablanian, JH Scott, HS Rugo, ... Breast cancer research and treatment 154, 339-349, 2015 | 76 | 2015 |
| A phase II clinical trial of pembrolizumab and enobosarm in patients with androgen receptor‐positive metastatic triple‐negative breast cancer Y Yuan, JS Lee, SE Yost, PH Frankel, C Ruel, CA Egelston, W Guo, ... The oncologist 26 (2), 99-e217, 2021 | 67 | 2021 |
| Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer Y Yuan, JS Lee, SE Yost, PH Frankel, C Ruel, CA Egelston, W Guo, ... European Journal of Cancer 154, 11-20, 2021 | 60 | 2021 |
| Circulating tumor cells in breast cancer: applications in personalized medicine JS Lee, MJM Magbanua, JW Park Breast cancer research and treatment 160, 411-424, 2016 | 55 | 2016 |
| Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time (CALGB 40502 and CALGB 40503, Alliance) MJM Magbanua, HS Rugo, DM Wolf, L Hauranieh, R Roy, P Pendyala, ... Clinical Cancer Research 24 (6), 1486-1499, 2018 | 45 | 2018 |
| Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer JS Lee, SE Yost, S Blanchard, D Schmolze, HH Yin, R Pillai, K Robinson, ... Breast Cancer Research 21, 1-13, 2019 | 39 | 2019 |
| Phase II Trial of Neoadjuvant Carboplatin and Nab‐Paclitaxel in Patients with Triple‐Negative Breast Cancer Y Yuan, JS Lee, SE Yost, SM Li, PH Frankel, C Ruel, D Schmolze, ... The Oncologist 26 (3), e382-e393, 2021 | 35 | 2021 |
| A novel strategy for detection and enumeration of circulating rare cell populations in metastatic cancer patients using automated microfluidic filtration and multiplex immunoassay MJM Magbanua, M Pugia, JS Lee, M Jabon, V Wang, M Gubens, ... PLoS One 10 (10), e0141166, 2015 | 29 | 2015 |
| Synchronous detection of circulating tumor cells in blood and disseminated tumor cells in bone marrow predicts adverse outcome in early breast cancer MJM Magbanua, C Yau, DM Wolf, JS Lee, A Chattopadhyay, JH Scott, ... Clinical Cancer Research 25 (17), 5388-5397, 2019 | 27 | 2019 |
| Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive … C Egelston, W Guo, S Yost, JS Lee, D Rose, C Avalos, J Ye, P Frankel, ... Journal for Immunotherapy of Cancer 9 (3), 2021 | 24 | 2021 |
| Antibody–drug conjugates in breast cancer: current status and future directions C Mark, JS Lee, X Cui, Y Yuan International Journal of Molecular Sciences 24 (18), 13726, 2023 | 23 | 2023 |
| Analysis of gut microbiome using explainable machine learning predicts risk of diarrhea associated with tyrosine kinase inhibitor neratinib: a pilot study CW Wong, SE Yost, JS Lee, JD Gillece, M Folkerts, L Reining, ... Frontiers in oncology 11, 604584, 2021 | 22 | 2021 |
| Sarcoma of the breast: clinical characteristics and outcomes of 991 patients from the national cancer database JS Lee, K Yoon, M Onyshchenko Sarcoma 2021 (1), 8828158, 2021 | 22 | 2021 |
| CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer: translational research, clinical trials, and future directions JS Lee, H Hackbart, X Cui, Y Yuan International Journal of Molecular Sciences 24 (14), 11791, 2023 | 14 | 2023 |
| Genomic markers of CDK 4/6 inhibitor resistance in hormone receptor positive metastatic breast cancer JS Lee, SE Yost, SM Li, Y Cui, PH Frankel, YC Yuan, D Schmolze, ... Cancers 14 (13), 3159, 2022 | 14 | 2022 |
| A phase II clinical trial of pembrolizumab and selective androgen receptor modulator GTx-024 in patients with advanced androgen receptor-positive triple-negative breast cancer. JS Lee-Bitar, PH Frankel, SE Yost, TW Synold, N Martinez, A Tang, ... Journal of Clinical Oncology 37 (15_suppl), 1069-1069, 2019 | 9 | 2019 |
| Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer X Ge, SE Yost, JS Lee, PH Frankel, C Ruel, Y Cui, M Murga, A Tang, ... Cancers 14 (17), 4279, 2022 | 5 | 2022 |
| Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer Y Yuan, JS Lee, SE Yost, T Stiller, MS Blanchard, S Padam, V Katheria, ... Journal of geriatric oncology 12 (5), 752-758, 2021 | 5 | 2021 |
| Gut microbiome predicts response to CDK4/6 inhibitor and immune check point inhibitor combination in patients with hormone receptor positive metastatic breast cancer CW Wong, SE Yost, JS Lee, SK Highlander, Y Yuan Cancer Research 81 (13_Supplement), 336-336, 2021 | 4 | 2021 |
